Donor experience As a leader in plasma collection, CSL has continued to innovate and improve the donor experience, raising the safety and effectiveness of the donation process, improving health equity in donor communities, and ensuring that the donor is acknowledged for their contribution that is essential to the supply of life-saving plasma-derived therapies for patients. Improving donor experience through individualised nomograms A notable initiative within the donor experience focus area is the addition of the Rika Plasma Donation System™ to CSL’s Donation Centres. The clinical trial to support the FDA approval of the Rika system, achieved in 2024 showed an average 10% increase in the volume of plasma collected per donation with an average collection time of less than 35 minutes. This initiative was followed by the introduction of Rika Plasma Donation System™’s Individualised Nomogram, iNomi™, which over the reporting period has been made available in each plasma centre within the U.S. and Puerto Rico. iNomi™ allows plasma donors to donate an amount of plasma based on weight, height and haematocrit, while maintaining the same collection time. Improvements in targeted nomogram collections through iNomi™ allow CSL to more safely target a donor’s collection volume. This enables CSL to collect more plasma from some donors, helping to meet the growing demand for plasma-derived therapies. Donor safety is maintained throughout the process and on average, some donors may give less than they did previously. It takes a village of generous donors As the number of patients who need plasma-derived therapies increase, patients are thankful to plasma donors, especially because it takes a significant amount of donations from donors to make CSL’s plasma-derived therapies possible: 130 plasma donations are needed to treat one primary immunodeficiency patient for one year 1,000 are needed to treat one hereditary angioedema patient for one year 900 are needed to treat one Alpha-1 Antitrypsin deficiency patient for one year 1,200 are needed to treat one severe haemophilia patient for one year TIM’S STORY Tim, a father of four and an avid outdoor adventurer, lives fully while managing haemophilia A, a rare bleeding disorder. From mountain biking to mentoring young athletes, Tim has learned to deftly balance treatment, family, and adventure. His story proves that rare conditions can’t limit a life well-lived. 31 CSL Limited Annual Report 2024/25
RkJQdWJsaXNoZXIy MjE2NDg3